Contract research organisations (CROs) in Andhra Pradesh, India have set up a forum designed to improve the transparency of clinical research conducted in the region.
Esoterix Clinical Trials Services has forged a strategic alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access to enhanced assay development services.
Companies outsourcing patient recruitment in emerging markets should have more people on the ground, according to Cutting Edge Information's Shaylyn Pike.
Open source clinical trial software company OpenClinica has launched a marketing agreement with Athena Healthcare Consultancy to work within the Chinese market.
Biocon’s Indian unit Clinigene International has partnered with US counterpart Spaulding Clinical Research LLC to provide clinical pharmacology services.
The EMA says current GCP rules make quality management in trials too costly and need to be revised into a code that meets the needs of academics, small and midsized drugmakers and Big Pharmas alike.
Russian authorities need to dedicate more resources to reviewing trial applications ahead of new site accreditation rules due to come into effect later this year according to report on the country’s contract research sector.
The CEO of Covance has warned it will be “very, very difficult” for CROs expanding through M&A to integrate assets, and the process could see clients go elsewhere.
An evidence-based approach to planning during protocol development is key to successful patient recruitment according to Joseph Kim, director of clinical operations at Shire Pharmaceuticals.
INC Research CEO James Ogle tells Outsourcing-pharma.com that the acquisition of fellow CRO Kendle was about building a presence in emerging trial hotspots and pharmaceutical markets.
In June global drug giant Pfizer began what it described as the world’s first ‘virtual trial’ using mobile technology to collect data from patients in their own homes rather than at research sites.
PPD posted an improved set of financials for Q2 days after announcing a review of its long-term plan and capital structure following speculation it was looking for a buyer.
The acquisition of site optimisation specialist Firecrest is good news for customers including US drug giant Pfizer says Alan Morgan, group president of clinical services at Icon.
India’s Central drugs standard control organisation (CDSCO) has issued new draft guidance of clinical trials and new drug approvals that pave the way for potential electronic submissions.
An equity analyst has downgraded Icon and Parexel, following the Irish CRO’s Q2 results, and warned that its “enthusiasm for strategic deals is waning”.
Outsourcing-Pharma presents a round-up of CRO M&A, including inVentiv closing the PharmaNet deal, Icon adding technology, and Bracket inking its first takeover.
